Effect of calcium and vitamin D in treatment of gestational diabetes
Phase 2
- Conditions
- Gestational diabetes mellitus.Diabetes mellitus in pregnancy, unspecifiedO24.9
- Registration Number
- IRCT201311205623N11
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 56
Inclusion Criteria
Pregnant women aged 18-40 years; diagnosed with GDM at 24-28 weeks' gestation
Exclusion Criteria
Subjects with premature preterm rupture of membrane
Placenta abruption
Pre-eclampsia
Eclampsia
Chronic hypertension
Hypothyroidism
Urinary tract infection
Smoking
Those with kidney or liver diseases
Those taking estrogen therapy
Stressful life conditions
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: t Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.